Fulltext

Dose-Response Relationships Following Oral Administration of DuP 753 to Normal Humans

Christen, Y. ; Waeber, B. ; Nussberger, J. ; Lee, R.J. ; Timmermans, Pieter B.M.W.M. ; Brunner, H.R.

In: American Journal of Hypertension, 1991, vol. 4, no. 4_Pt_2, p. 350S-353S

Aggiungi alla tua lista
    Titre
    • Dose-Response Relationships Following Oral Administration of DuP 753 to Normal Humans
    Auteur
    • Christen, Y.. Hypertension Division and Cardiovascular Research Group, University Hospital, Lausanne, Switzerland
    • Waeber, B.. Hypertension Division and Cardiovascular Research Group, University Hospital, Lausanne, Switzerland
    • Nussberger, J.. Hypertension Division and Cardiovascular Research Group, University Hospital, Lausanne, Switzerland
    • Lee, R.J.. E. I. du Pont de Nemours & Company, Medical Products Dept., Wilmington, Delaware, USA, and Geneva, Switzerland.
    • Timmermans, Pieter B.M.W.M.. E. I. du Pont de Nemours & Company, Medical Products Dept., Wilmington, Delaware, USA, and Geneva, Switzerland.
    • Brunner, H.R.. Hypertension Division and Cardiovascular Research Group, University Hospital, Lausanne, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • American Journal of Hypertension, 1991, vol. 4, no. 4_Pt_2, p. 350S-353S. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:289720
    Summary
    We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, on the pressor action of exogenous angiotensin I and II in healthy volunteers. In a single dose study, doses of 2.5, 5, 10, 20, and 40 mg of DuP 753 or placebo were tested serially at one week intervals. In the multiple dose study, the administration of placebo or DuP 753 (5, 10, 20, or 40 mg, per os once daily) for eight consecutive days was evaluated. The blood pressure response to angiotensin I and II was inhibited in a dose-dependent fashion with a blocking effect still present 24 h post drug. DuP 753 also induced a dose-dependent compensatory rise in plasma renin. This new compound was well tolerated by these normal volunteers. Thus, DuP 753 appears to be a well tolerated, orally active, potent and long-lasting antagonist of angiotensin II in humans. Am J Hypertens 1991;4:350S-354S